Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.88 |
| ▸ | HMGCR | P04035 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL4372285 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL1426398 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL2411531 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL7060057 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL633793 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL11857836 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL4819877 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL8400312 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL2593972 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL11519286 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6468560-B2 | NERVOUS SYSTEM DISORDERS; ALZHEIMER'S DISEASE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-10-22 | — | — | US | claimed |
| WO-2024212009-A1 | SENSORS FOR DETECTING TARGET NUCLEIC ACIDS AND THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-10-17 | — | — | WO | disclosed |
| US-11806419-B2 | Aptamers for odor control applications | THE PROCTER & GAMBLE COMPANY (US) | 2023-11-07 | — | — | US | disclosed |
| EP-3956451-A1 | APTAMERS FOR ODOR CONTROL APPLICATIONS | The Procter & Gamble Company (US) | 2022-02-23 | — | — | EP | disclosed |
| US-7309584-B2 | Mutations of the MDR1 P-glycoprotein that improves its ability to confer resistance to chemotherapeutic drugs | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-12-18 | — | — | US | disclosed |
| US-20060093689-A1 | Skin cosmetics | TAKASAGO INTERNATIONAL CORPORATION | 2006-05-04 | — | — | US | disclosed |
| EP-1428523-A1 | Skin cosmetics | Takasago International Corporation (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-20040086882-A1 | Mutations of the mdr1 p-glycoprotein that improves its ability to confer resistance to chemotherapeutic drugs | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-05-06 | — | — | US | disclosed |
| US-20030104495-A1 | Sperm-specific AKAP protein genes and uses | CARR DANIEL W (US) | 2003-06-05 | — | — | US | disclosed |
| US-6451528-B1 | ISOLATED NUCLEIC ACID ENCODING SPERM-SPECIFIC PROTEIN KINASE A ANCHORING PROTEINS FROM MAMMALIAN SPECIES, RECOMBINANT EXPRESSION CONSTRUCTS ENCODING SAID MAMMALIAN SPERM-SPECIFIC PROTEIN KINASE A ANCHORING PROTEINS, CELLS TRANSFORMED WITH | OREGON HEALTH & SCIENCES UNIVERSITY | 2002-09-17 | — | — | US | disclosed |
| WO-2002010205-A2 | MUTATIONS OF THE MDR1 P-GLYCOPROTEIN THAT IMPROVE ITS ABILITY TO CONFER RESISTANCE TO CHEMOTHERAPEUTIC DRUGS | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2002-02-07 | — | — | WO | disclosed |
| US-6066442-A | USED TO MAGNETIC TAPES, FLOPPY DISKS, FLEXIBLE SUBSTRATA, MATERIALS FOR MEMBRANE SWITCHES, RECORDING SHEET FOR PRINTERS: COMPRSIES AN ELECTROCONDUCTIVE LAYER CONTAINING METAL OXIDE PARTICLES AND POLYMER PARTICLES | KONICA CORPORATION (JP) | 2000-05-23 | — | — | US | disclosed |
| US-5849499-A | Monoclonal antibody to acetylated lysine residues in recombinant bovine somatotropin | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0772082-A1 | Plastic film with antistatic layer and silver halide light-sensitive photographic element using the same | KONICA CORPORATION (JP) | 1997-05-07 | — | — | EP | disclosed |
| EP-0754966-A1 | Silver halide light-sensitive photographic material and processing method thereof | KONICA CORPORATION (JP) | 1997-01-22 | — | — | EP | disclosed |
| EP-0485525-B1 | MONOCLONAL ANTIBODY TO ACETYLATED LYSINE RESIDUES IN RECOMBINANT BOVINE SOMATOTROPIN | UPJOHN CO (US) | 1994-09-14 | — | — | EP | disclosed |
| EP-0485525-A1 | MONOCLONAL ANTIBODY TO ACETYLATED LYSINE RESIDUES IN RECOMBINANT BOVINE SOMATOTROPIN. | UPJOHN CO (US) | 1992-05-20 | — | — | EP | disclosed |
| WO-1991002080-A2 | MONOCLONAL ANTIBODY TO ACETYLATED LYSINE RESIDUES IN RECOMBINANT BOVINE SOMATOTROPIN | THE UPJOHN COMPANY (US) | 1991-02-21 | — | — | WO | disclosed |
| US-4585530-A | Process for forming adherent chromium electrodeposits from high energy efficient bath on ferrous metal substrates | M&T CHEMICALS INC. (US) | 1986-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11806419-B2 | Aptamers for odor control applications | TAS2R40, TAS2R10, OR10J3 | MEN1 3467/4885ALDH1A1 2521/4885HMGCR 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.